| GTO ID | GTC3500 |
| Trial ID | NCT05933577 |
| Disease | Melanoma |
| Therapy | mRNA vaccine |
| Treatment | V940|mRNA-4157 |
| Co-treatment | Pembrolizumab |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma |
| Year | 2023 |
| Country | Australia|Canada|Chile|Poland|Portugal|Spain|Turkey |
| Company sponsor | Merck Sharp & Dohme LLC |
| Other ID(s) | V940-001|V940-001|2023-503652-27-00 |
| Vector information | |||
|
|||
| Cohort1: V940 | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||